CJ CheilJedang launches microbiome subsidiary

Home > Business > Industry

print dictionary print

CJ CheilJedang launches microbiome subsidiary

From left: CJ CheilJedang CEO Choi Eun-seok, CJ Bioscience CEO Chun Jong-sik and CJ CheilJedang's Bioscience division head Hwang Yun-il pose at a ceremony to celebrate the establishment of CJ Bioscience on Tuesday. [CJ CHEILJEDANG]

From left: CJ CheilJedang CEO Choi Eun-seok, CJ Bioscience CEO Chun Jong-sik and CJ CheilJedang's Bioscience division head Hwang Yun-il pose at a ceremony to celebrate the establishment of CJ Bioscience on Tuesday. [CJ CHEILJEDANG]

 
CJ CheilJedang officially launched bio pharmaceutical subsidiary CJ Bioscience on Wednesday, with goals to lead the so-called microbiome industry.
 
The subsidiary’s focus will be drugs and health supplements based on microbiomes, a term referring to genetic material in microorganisms. According to the company, microbiomes are used in drugs that treat digestive disorders, obesity, diabetes, cancer and Alzheimer's.
  
The CEO of the new company will be Chun Jong-sik, founder of local microbiome research company ChunLab.  
 
Chun Lab was acquired by CJ CheilJedang last year to strengthen the company’s bio business. In July, it acquired 43.99 percent of ChunLab, renaming the company CJ Bioscience.  
 
It acquired a 75.8 percent stake in Dutch bio firm Batavia Biosciences in November.  
 
CJ Bioscience will focus on research and development in the cohort study stage, a clinical process involving specific trial groups, to acquire more microbiome data. The company says it will be able to speed up the development of new drugs and the success rates of its clinical trials.  

 
Apart from drugs, it will aim to manufacture and sell health supplements. It will also expand into the next generation sequencing sector, an area that determines the genetic sequence of DNA and RNA to study genetic variations related to diseases.  
 
The company will also try to get contract and development manufacturing organization (CDMO) deals.  
 
“In the next two to three years, we will aim for the pipelines of our cancer and autoimmune disease treatments to start U.S. Food and Drug Administration’s phase 1 trials and license them out through joint research with big global pharmaceutical companies,” said CEO Chun.
 
 

BY LEE TAE-HEE [lee.taehee2@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now